Astex Pharmaceuticals, Inc.
Trending Investment Opportunities
Advertisement
today announced topline results from the ongoing phase 2 of
SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study
of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course.
As of end of June data cutoff, 67 AML patients had a minimum follow up of 3
months (50 patients representing the complete cohort of relapsed/refractory
AML, and 17 patients in the treatment-naive elderly AML not suitable for
induction chemotherapy cohort). The primary endpoint is overall remission rate
(Complete Remission or CR; Complete Remission with Incomplete hematologic
recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9
remissions in treatment-naive elderly AML for an overall complete remission
rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results have been submitted
for presentation to the American Society of Hematology (ASH) meeting to be
held later this year during December 7-10 in New Orleans, LA.
Loading...
Loading...
ASTXTradr 2X Long ASTS Daily ETF Tradr 2X Long ASTS Daily ETF
$41.9018.8%
Edge Rankings
Momentum
N/A
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.